Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab

License For Prolia And Xgeva Rivals Follows Ustekinumab Deal With Bio-Thera

Building A Brick Wall, Bricklayers
The next piece has fallen into place for Hikma’s US biosimilars business • Source: Alamy

More from Deals

More from Business